464 related articles for article (PubMed ID: 36186781)
1. Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment.
Franson A; McClellan BL; Varela ML; Comba A; Syed MF; Banerjee K; Zhu Z; Gonzalez N; Candolfi M; Lowenstein P; Castro MG
Front Med (Lausanne); 2022; 9():966458. PubMed ID: 36186781
[TBL] [Abstract][Full Text] [Related]
2. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
Front Immunol; 2022; 13():867154. PubMed ID: 35603195
[TBL] [Abstract][Full Text] [Related]
3. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy: a promising approach for glioma treatment.
Yasinjan F; Xing Y; Geng H; Guo R; Yang L; Liu Z; Wang H
Front Immunol; 2023; 14():1255611. PubMed ID: 37744349
[TBL] [Abstract][Full Text] [Related]
5. Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.
Chelliah SS; Paul EAL; Kamarudin MNA; Parhar I
Molecules; 2021 Feb; 26(4):. PubMed ID: 33671796
[TBL] [Abstract][Full Text] [Related]
6. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
Pachocki CJ; Hol EM
J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
[TBL] [Abstract][Full Text] [Related]
7. Glioma Stem Cells in Pediatric High-Grade Gliomas: From Current Knowledge to Future Perspectives.
Da-Veiga MA; Rogister B; Lombard A; Neirinckx V; Piette C
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565425
[TBL] [Abstract][Full Text] [Related]
8. Applications and current challenges of chimeric antigen receptor T cells in treating high-grade gliomas in adult and pediatric populations.
Jovanovich N; Habib A; Hameed NF; Edwards L; Zinn PO
Immunotherapy; 2023 Apr; 15(5):383-396. PubMed ID: 36876438
[TBL] [Abstract][Full Text] [Related]
9. Impact of redox-related genes on tumor microenvironment immune characteristics and prognosis of high-grade gliomas.
Yuan Y; Zuo M; Zhang S; Chen S; Feng W; Wang Z; Chen M; Liu Y
Front Cell Neurosci; 2023; 17():1155982. PubMed ID: 37252189
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
[TBL] [Abstract][Full Text] [Related]
11. The Landscape of Pediatric High-Grade Gliomas: The Virtues and Pitfalls of Pre-Clinical Models.
Furst LM; Roussel EM; Leung RF; George AM; Best SA; Whittle JR; Firestein R; Faux MC; Eisenstat DD
Biology (Basel); 2024 Jun; 13(6):. PubMed ID: 38927304
[TBL] [Abstract][Full Text] [Related]
12. Gene Therapy for High Grade Glioma: The Clinical Experience.
Varela ML; Comba A; Faisal SM; Argento A; Franson A; Barissi MN; Sachdev S; Castro MG; Lowenstein PR
Expert Opin Biol Ther; 2023 Feb; 23(2):145-161. PubMed ID: 36510843
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T Cell and Chimeric Antigen Receptor NK Cell Therapy in Pediatric and Adult High-Grade Glioma-Recent Advances.
Kowalczyk A; Zarychta J; Marszołek A; Zawitkowska J; Lejman M
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339374
[TBL] [Abstract][Full Text] [Related]
14. IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma.
Rechberger JS; Porath KA; Zhang L; Nesvick CL; Schrecengost RS; Sarkaria JN; Daniels DJ
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631512
[TBL] [Abstract][Full Text] [Related]
15. Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities.
Linares CA; Varghese A; Ghose A; Shinde SD; Adeleke S; Sanchez E; Sheriff M; Chargari C; Rassy E; Boussios S
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686020
[TBL] [Abstract][Full Text] [Related]
16. Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH).
Benesch M; Wagner S; Berthold F; Wolff JE
J Neurooncol; 2005 Apr; 72(2):179-83. PubMed ID: 15925999
[TBL] [Abstract][Full Text] [Related]
17. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.
White K; Connor K; Meylan M; Bougoüin A; Salvucci M; Bielle F; O'Farrell AC; Sweeney K; Weng L; Bergers G; Dicker P; Ashley DM; Lipp ES; Low JT; Zhao J; Wen P; Prins R; Verreault M; Idbaih A; Biswas A; Prehn JHM; Lambrechts D; Arijs I; Lodi F; Dilcan G; Lamfers M; Leenstra S; Fabro F; Ntafoulis I; Kros JM; Cryan J; Brett F; Quissac E; Beausang A; MacNally S; O'Halloran P; Clerkin J; Bacon O; Kremer A; Chi Yen RT; Varn FS; Verhaak RGW; Sautès-Fridman C; Fridman WH; Byrne AT
Ann Oncol; 2023 Mar; 34(3):300-314. PubMed ID: 36494005
[TBL] [Abstract][Full Text] [Related]
18. Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy.
Mishchenko TA; Turubanova VD; Gorshkova EN; Krysko O; Vedunova MV; Krysko DV
Front Immunol; 2023; 14():1299064. PubMed ID: 38274827
[TBL] [Abstract][Full Text] [Related]
19. Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type.
Vallero SG; Bertero L; Morana G; Sciortino P; Bertin D; Mussano A; Ricci FS; Peretta P; Fagioli F
Front Oncol; 2022; 12():1082062. PubMed ID: 36727064
[TBL] [Abstract][Full Text] [Related]
20. Profile of nimotuzumab in the treatment of high-grade glioma.
Yang QY; Guo CC; Chen ZP
Onco Targets Ther; 2015; 8():819-25. PubMed ID: 25926743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
